阿霉素
LNCaP公司
癌细胞
药物输送
生物相容性
介孔二氧化硅
前列腺癌
纳米技术
癌症研究
材料科学
体内
癌症
化学
细胞凋亡
化疗
医学
介孔材料
生物化学
生物
内科学
冶金
催化作用
生物技术
作者
Changming Liu,Guang-Bing Chen,Hui-Hong Chen,Jiabin Zhang,Huizhang Li,Mingxiong Sheng,Wubin Weng,Shanming Guo
标识
DOI:10.1016/j.colsurfb.2018.12.038
摘要
Nanoparticular drug delivery system (NDDS) has great potential for enhancing the efficacy of traditional chemotherapeutic drugs. However, it is still a great challenge to fabricate a biocompatible NDDS with simple structure capable of optimizing therapeutic efficacy, such as high tumor accumulation, suitable drug release profile (e.g. no premature drug leakage in normal physiological conditions while having a rapid release in cancer cells), low immunogenicity, as well as good biocompatibility. In this work, a simple core/shell structured nanoparticle was fabricated for prostate cancer treatment, in which a mesoporous silica nanoparticle core was applied as a container to high-efficiently encapsulate drugs (doxorubicin, DOX), CaCO3 interlayer was designed to act as sheddable pH-sensitive gatekeepers for controlling drug release, and cancer cell membrane wrapped outlayer could improve the colloid stability and tumor accumulation capacity. In vitro cell experiments demonstrated that the as-prepared nanovehicles (denoted as DOX/[email protected]3@CM) could be efficiently uptaken by LNCaP-AI prostate cancer cells and even exhibited a better anti-tumor efficiency than free DOX. In addition, Live/Dead cell detection and apoptosis experiment demonstrated that MSN/[email protected]3@CM could effectively induce apoptosis-related death in prostate cancer cells. In vivo antitumor results demonstrated that DOX/[email protected]3@CM administration could remarkably suppress the tumor growth. Compared with other tedious approaches to optimize the therapeutic efficacy, this study provides an effective drug targeting system only using naturally biomaterials for the treatment of prostate cancer, which might have great potential in clinic usage.
科研通智能强力驱动
Strongly Powered by AbleSci AI